- Home
- Companies
- C2N Diagnostics
- Products
- PrecivityAD - Alzheimer’s Disease Blood ...
PrecivityAD - Alzheimer’s Disease Blood Test
The PrecivityAD™ test is an innovative new blood test intended for use in patients with cognitive impairment. The test aims to help physicians better determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.
The PrecivityAD™ test identifies whether a patient is likely to have amyloid plaques in the brain. The test relies on precise and robust quantitation of the Amyloid Beta 42/40 ratio (Aβ 42/40) and detection of the Apolipoprotein E proteotype (equivalent to ApoE genotype) in blood samples, using C2N’s proprietary mass spectrometry platform.
The PrecivityAD™ test is intended for use in individuals experiencing memory and thinking issues. The test is only available through an order by a physician.
The test is available in 48 states, the District of Columbia, and Puerto Rico; the exceptions are Maryland and New York, which require individual state processes for CLIA labs. C2N is working toward obtaining the requisite certifications that will permit the PrecivityAD™ test to be available in these states in the near future. Please periodically refer back to this website or contact C2N at 1.877.226.3424 for status updates on test availability in these two states.
The early manifestations of many neurological diseases, including memory disorders like Alzheimer’s disease, make it very difficult to properly diagnose early in the course of disease. Early detection is imperative to early treatment and offering the greatest chance to slow or halt the progression of disease. Given the importance of early detection and accurate diagnosis, C2N is developing a comprehensive Brain Health Panel that will measure multiple features of Alzheimer’s disease and related disorders. Tests in the pipeline include different forms of Tau proteins and neurofilament light chain protein, among others.